Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Other Non-Current Assets (2023 - 2025)

Silence Therapeutics (SLN) has disclosed Other Non-Current Assets for 3 consecutive years, with $399000.0 as the latest value for Q3 2025.

  • Quarterly Other Non-Current Assets changed N/A to $399000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $399000.0 through Sep 2025, changed N/A year-over-year, with the annual reading at $356000.0 for FY2024, 90.24% down from the prior year.
  • Other Non-Current Assets hit $399000.0 in Q3 2025 for Silence Therapeutics, down from $3.9 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $3.9 million in Q2 2025 to a low of $356000.0 in Q4 2024.
  • Historically, Other Non-Current Assets has averaged $2.3 million across 3 years, with a median of $3.2 million in 2023.
  • Biggest YoY gain for Other Non-Current Assets was 88.88% in 2024; the steepest drop was 88.88% in 2024.
  • Year by year, Other Non-Current Assets stood at $3.2 million in 2023, then tumbled by 88.88% to $356000.0 in 2024, then increased by 12.08% to $399000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for SLN at $399000.0 in Q3 2025, $3.9 million in Q2 2025, and $3.6 million in Q1 2025.